The DOI matches its OpenAlex record; 47 of the 47 references it cites were found in a registry or an index.
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Abstract
This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,094
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
New Tables for Multiple Comparisons with a Control
Dunnett, C. W. (1964) · Biometrics · doi:10.2307/2528490 · Cited by 3,113
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
The homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788
Dunaif, A., Scott, D., Finegood, D., Quintana, B., & Whitcomb, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 524
Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., Digby, J. E., Sewter, C. P., Lazar, M. A., Chatterjee, V. K., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119870 · Cited by 517
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Emoto, M., Nishizawa, Y., Maekawa, K., Hiura, Y., Kanda, H., Kawagishi, T., Shoji, T., Okuno, Y., & Morii, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.818 · Cited by 457
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Elbrecht, A., Chen, Y., Cullinan, C. A., Hayes, N., Leibowitz, M. D., Moller, D. E., & Berger, J. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1044 · Cited by 384
Nestler, J. E., & Jakubowicz, D. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4431 · Cited by 368
Kelly, I. E., Han, T. S., Walsh, K., & Lean, M. E. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.288 · Cited by 315
Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat
Haliakon, S., Doaré, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.-F., Dugail, I., Morin, J., Auwerx, J., & Ferré, P. (1997) · Diabetes · doi:10.2337/diab.46.9.1393 · Cited by 306
Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., & Ikeda, Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.908 · Cited by 281
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes
Hermans, M. P., Levy, J. C., Morris, R. J., & Turner, R. C. (1999) · Diabetologia · doi:10.1007/s001250051215 · Cited by 260
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · PubMed · Cited by 229
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy
Imano, E., Kanda, T., Nakatani, Y., Nishida, T., Arai, K., Motomura, M., Kajimoto, Y., Yamasaki, Y., & Hori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2135 · Cited by 196
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Iwamoto, Y., Kosaka, K., Kuzuya, T., Akanuma, Y., Shigeta, Y., & Kaneko, T. (1996) · Diabetes Care · doi:10.2337/diacare.19.2.151 · Cited by 179
Insulin resistance and coronary heart disease
Laakso, M. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199608000-00008 · Cited by 152
Impaired Glucose Tolerance is Normalized by Treatment With the Thiazolidinedione Troglitazone
Antonucci, T. K., Whitcomb, R. W., McLain, R. W., & Lockwood, D. H. (1997) · Diabetes Care · doi:10.2337/diacare.20.2.188 · Cited by 142
Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients
Shimizu, H., Tsuchiya, T., Sato, N., Shimomura, Y., Kobayashi, I., & Mori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1470 · Cited by 115
The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent
Cantello, B. C. C., Cawthorne, M. A., Haigh, D., Hindley, R. M., Smith, S. A., & Thurlby, P. L. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80325-5 · Cited by 112
Fonseca, V. A., Valiquett, T. R., Huang, S. M., Ghazzi, M. N., & Whitcomb, R. W. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5123 · Cited by 110
Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts
Kellerer, M., Kroder, G., Tippmer, S., Berti, L., Kiehn, R., Mosthaf, L., & Häring, H. U. (1994) · Diabetes · doi:10.2337/diab.43.3.447 · Cited by 87
Fatal Hepatotoxicity Associated with Troglitazone
Vella, A. V., de Groen, P. C., & Dinneen, S. F. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00032 · Cited by 76
Overweight: Fat Distribution and Health Risks. Epidemiological Observations
Seidell, J. C., HAUTVAST, J. G. A. J., & Deurenberg, P. (1989) · Transfusion Medicine and Hemotherapy · doi:10.1159/000222401 · Cited by 43
Insulin and polycystic ovary syndrome: A new look at an old subject
Ciampelli, M., & Lanzone, A. (1998) · Gynecological Endocrinology · doi:10.3109/09513599809015601 · Cited by 42
Shinozaki, K., Hattori, Y., Suzuki, M., Hara, Y., Kanazawa, A., Takaki, H., Tsushima, M., & Harano, Y. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.3302 · Cited by 36
Troglitazone has no effect on red cell mass or other erythropoietic parameters
Young, M. M. R., Squassante, L., Wemer, J., van Marle, S. P., Dogterom, P., & Jonkman, J. H. G. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050602 · Cited by 33
Allauzen, S., Mani, J. C., Granier, C., Pau, B., & Bouanani, M. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00020-b · Cited by 33
Allauzen, S. (1995) · Molecular Immunology · doi:10.1016/0161-5890(94)00133-l · Cited by 29
'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease
Chaour, M., Théroux, P., Gilfix, B. M., CAMPEAU, L. A., Lespérance, J., Ghitescu, M., Gelinas, F., & Solymoss, B. (1997) · Coronary Artery Disease · doi:10.1097/00019501-199711000-00002 · Cited by 17
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Cited by
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
Self-citationGoldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Metadata
- Authors
- Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2001-01-01
- Volume
- 86
- Issue
- 1
- Pages
- 280-288
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2056726092
- Cited by
- 518
- References
- 47
- FWCI
- 33.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.